Log in
NYSEAMERICAN:MTNB

Matinas BioPharma Stock Forecast, Price & News

$0.90
+0.01 (+1.13 %)
(As of 10/23/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.86
Now: $0.90
$0.91
50-Day Range N/A
52-Week Range
$0.49
Now: $0.90
$2.49
Volume606,909 shs
Average Volume2.29 million shs
Market Capitalization$178.14 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.
Read More
Matinas BioPharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 3.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.86 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:MTNB
CUSIPN/A
CIKN/A
Phone+1-908-4431860
Employees21

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$178.14 million
Next Earnings Date11/6/2020 (Confirmed)
OptionableNot Optionable
$0.90
+0.01 (+1.13 %)
(As of 10/23/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MTNB News and Ratings via Email

Sign-up to receive the latest news and ratings for MTNB and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Matinas BioPharma (NYSEAMERICAN:MTNB) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Matinas BioPharma?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Matinas BioPharma in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Matinas BioPharma
.

When is Matinas BioPharma's next earnings date?

Matinas BioPharma is scheduled to release its next quarterly earnings announcement on Friday, November 6th 2020.
View our earnings forecast for Matinas BioPharma
.

How can I listen to Matinas BioPharma's earnings call?

Matinas BioPharma will be holding an earnings conference call on Friday, November 6th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Matinas BioPharma's earnings last quarter?

Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) announced its earnings results on Monday, August, 10th. The company reported ($0.03) earnings per share for the quarter, meeting the consensus estimate of ($0.03).
View Matinas BioPharma's earnings history
.

What price target have analysts set for MTNB?

5 analysts have issued 12 month price targets for Matinas BioPharma's stock. Their forecasts range from $3.00 to $4.00. On average, they expect Matinas BioPharma's share price to reach $3.30 in the next twelve months. This suggests a possible upside of 268.6% from the stock's current price.
View analysts' price targets for Matinas BioPharma
.

Who are some of Matinas BioPharma's key competitors?

What other stocks do shareholders of Matinas BioPharma own?

Who are Matinas BioPharma's key executives?

Matinas BioPharma's management team includes the following people:
  • Mr. Jerome D. Jabbour J.D., Co-Founder, CEO, Pres & Director (Age 46, Pay $644.79k)
  • Mr. Keith A. Kucinski CPA, M.B.A., Chief Financial Officer (Age 50, Pay $249.05k)
  • Dr. Theresa Matkovits, Chief Devel. Officer (Age 53, Pay $380.62k)
  • Dr. James J. Ferguson, Chief Medical Officer (Age 67, Pay $461.46k)
  • Dr. Raphael J. Mannino, Chief Scientific Officer (Age 73)

What is Matinas BioPharma's stock symbol?

Matinas BioPharma trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "MTNB."

How do I buy shares of Matinas BioPharma?

Shares of MTNB can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Matinas BioPharma's stock price today?

One share of MTNB stock can currently be purchased for approximately $0.90.

How big of a company is Matinas BioPharma?

Matinas BioPharma has a market capitalization of $178.14 million. Matinas BioPharma employs 21 workers across the globe.

What is Matinas BioPharma's official website?

The official website for Matinas BioPharma is www.matinasbiopharma.com.

How can I contact Matinas BioPharma?

Matinas BioPharma's mailing address is SUITE 302, 1545 ROUTE 206 SOUTH, BEDMINSTER, NJ 7921, United States. The company can be reached via phone at +1-908-4431860.

This page was last updated on 10/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.